Theraclone Sciences

theraclone-sciences.com

Theraclone Sciences leverages its advanced screening technology to identify rare human monoclonal antibodies that can effectively combat infections and diseases. With over a decade of experience, the company has developed a platform for discovering therapeutic products, successfully licensing its HIV broadly neutralizing antibodies to Gilead for HIV-cure regimens and its technology to Onco Response for oncology applications. This positions Theraclone as a key player in the biotech industry, focusing on innovative antibody therapies with significant market potential.